Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Zobair M. Younossi, Pegah Golabi, Leyla de Avila, et al.
Journal of Hepatology (2019) Vol. 71, Iss. 4, pp. 793-801
Closed Access | Times Cited: 1748

Showing 1-25 of 1748 citing articles:

Non-alcoholic fatty liver disease
Elizabeth E. Powell, Vincent Wai‐Sun Wong, Mary E. Rinella
The Lancet (2021) Vol. 397, Iss. 10290, pp. 2212-2224
Closed Access | Times Cited: 1778
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Daniel Q. Huang, Hashem B. El‐Serag, Rohit Loomba
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 18, Iss. 4, pp. 223-238
Open Access | Times Cited: 1309
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1100
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Thomas G. Cotter, Mary E. Rinella
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1851-1864
Closed Access | Times Cited: 967
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 631
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD
James M. Paik, Pegah Golabi, Youssef Younossi, et al.
Hepatology (2020) Vol. 72, Iss. 5, pp. 1605-1616
Closed Access | Times Cited: 621
The burden and risks of emerging complications of diabetes mellitus
Dunya Tomic, Jonathan E. Shaw, Dianna J. Magliano
Nature Reviews Endocrinology (2022) Vol. 18, Iss. 9, pp. 525-539
Open Access | Times Cited: 597
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 9, pp. 599-612
Closed Access | Times Cited: 569
NAFLD as a continuum: from obesity to metabolic syndrome and diabetes
Amélio F. Godoy‐Matos, Wellington S. Silva Júnior, Cynthia Melissa Valério
Diabetology & Metabolic Syndrome (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 477
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, et al.
Metabolism (2020) Vol. 111, pp. 154170-154170
Open Access | Times Cited: 437
Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States
Zobair M. Younossi, Maria Stepanova, Janus P. Ong, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 3, pp. 580-589.e5
Open Access | Times Cited: 415
The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)
Daniela Maria Tănase, Evelina Maria Gosav, Claudia Florida Costea, et al.
Journal of Diabetes Research (2020) Vol. 2020, pp. 1-16
Open Access | Times Cited: 392
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
Norbert Stefan, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 4, pp. 284-296
Closed Access | Times Cited: 390
Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association
P. Barton Duell, Francine K. Welty, Michael Miller, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2022) Vol. 42, Iss. 6
Open Access | Times Cited: 371
Neutrophils in chronic inflammatory diseases
Andrea Herrero-Cervera, Oliver Soehnlein, Ellinor Kenne
Cellular and Molecular Immunology (2022) Vol. 19, Iss. 2, pp. 177-191
Open Access | Times Cited: 369
Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
Patricia Rada, Águeda González‐Rodríguez, Carmelo García‐Monzón, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 9
Open Access | Times Cited: 362
Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy
Johanna C. Arroyave-Ospina, Zongmei Wu, Yana Geng, et al.
Antioxidants (2021) Vol. 10, Iss. 2, pp. 174-174
Open Access | Times Cited: 344
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Daniel Ferguson, Brian N. Finck
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 8, pp. 484-495
Open Access | Times Cited: 330
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis
Jingxuan Quek, Kai En Chan, Zhen Yu Wong, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 1, pp. 20-30
Closed Access | Times Cited: 326
Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies
Helen Jarvis, Dawn Craig, Robert Barker, et al.
PLoS Medicine (2020) Vol. 17, Iss. 4, pp. e1003100-e1003100
Open Access | Times Cited: 324
Screening for Prediabetes and Type 2 Diabetes
Karina W. Davidson, Michael J. Barry, Carol M. Mangione, et al.
JAMA (2021) Vol. 326, Iss. 8, pp. 736-736
Open Access | Times Cited: 317
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 6, pp. 393-406
Closed Access | Times Cited: 311
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits
Moritz Peiseler, Robert F. Schwabe, Jochen Hampe, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1136-1160
Open Access | Times Cited: 285
Changing epidemiology, global trends and implications for outcomes of NAFLD
Vincent Wai‐Sun Wong, Mattias Ekstedt, Grace Lai‐Hung Wong, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 842-852
Open Access | Times Cited: 268
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai–Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 248
Page 1 - Next Page

Scroll to top